AbbVie Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: ABBV Category:


AbbVie has continued to generate excellent results after its Allergan acquisition and growth in its oncology portfolio. The company’s blockbuster arthritis drug, Humira has seen a lower contribution to the top-line but is expected to remain a cash cow at least until its patent expiry in 2 years. The stock has a decent dividend yield and the company operates in non-cyclical industry. Its valuation appears quite reasonable at current levels and deserves an “Outperform” rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!